Navigation Links
Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
Date:6/4/2008

line that includes its lead compound, AR- 67, which is currently being investigated in a Phase I clinical study, as well as AR-12 and AR-42, two novel, preclinical, cancer therapies.

AR-67 is a novel, third-generation camptothecin analogue that has demonstrated high potency in preclinical studies and improved pharmacokinetic properties, as demonstrated by the increased stability of the active lactone form of AR-67 in blood samples. Preclinical studies and preliminary Phase I data confirm that AR-67 maintains a greater proportion of drug in the active lactone form as compared with approved second-generation products, a characteristic that Arno believes may translate to superior clinical activity. Moreover, the potential for oral administration may increase patient convenience. A Phase I clinical study of AR-67 in patients with advanced solid tumors is currently ongoing. Multiple Phase II studies are planned for initiation in 2008 in a variety of cancers, including glioblastoma multiforme (GBM), a highly aggressive form of brain cancer.

AR-12 is a PDK-1 inhibitor that targets the Akt pathway while also possessing activity in the endoplasmic reticulum (ER) stress and other pathways targeting apoptosis. Preclinical data have demonstrated that AR-12 has activity in a wide range of tumor types and shows promising activity in combination with several widely used anti-cancer agents including Avastin(R), Herceptin(R), Gleevec(R), Tarceva(R) and tamoxifen.

AR-42 is a targeted inhibitor of the Pan-DAC and Akt pathways. In preclinical studies, AR-42 has demonstrated greater potency and a competitive profile in tumors when compared with vorinostat (SAHA), the leading marketed histone deacetylase inhibitor. Arno plans to initiate Phase I studies of AR-42 and AR-12 in early 2009.

Arie Belldegrun, M.D., FACS, Chairman of the Board of Directors of Arno added, "This is an important milestone for our company. Attracting sufficient capital was a key objectiv
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
10. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
11. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... YORK , Sept. 16, 2014  This report analyzes ... Units, The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Devices, and Medication. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
(Date:9/16/2014)... 16, 2014 Adaptive Biotechnologies, a clinical stage ... profile the adaptive immune system, is pleased to announce ... Commercial Officer (CCO). The addition of Brain to the ... from leading global healthcare companies, including Dean Schorno ... from Genomic Health and Sean Nolan (CTO) ...
Breaking Medicine Technology:Global Digital Radiography Industry 2Global Digital Radiography Industry 3Global Digital Radiography Industry 4Global Digital Radiography Industry 5Global Digital Radiography Industry 6Global Digital Radiography Industry 7Global Digital Radiography Industry 8Global Digital Radiography Industry 9Global Digital Radiography Industry 10Global Digital Radiography Industry 11Global Digital Radiography Industry 12Global Digital Radiography Industry 13Global Digital Radiography Industry 14Global Digital Radiography Industry 15Global Digital Radiography Industry 16Global Digital Radiography Industry 17Global Digital Radiography Industry 18Global Digital Radiography Industry 19Global Digital Radiography Industry 20Global Digital Radiography Industry 21Global Digital Radiography Industry 22Global Foot Care Products Industry 2Global Foot Care Products Industry 3Global Foot Care Products Industry 4Global Foot Care Products Industry 5Global Foot Care Products Industry 6Global Foot Care Products Industry 7Global Foot Care Products Industry 8Global Foot Care Products Industry 9Global Foot Care Products Industry 10Global Foot Care Products Industry 11Global Foot Care Products Industry 12Global Foot Care Products Industry 13Global Foot Care Products Industry 14Global Foot Care Products Industry 15
... Oncology, Inc. formerly Champions Biotechnology, Inc. (OTC: CSBR) reported ... First Quarter Financial Results:Total operating revenues for the first ... $1.60 million in the first quarter of fiscal 2011. ... 2012 were $3.85 million compared to $2.20 million in ...
... SAN DIEGO, Sept. 13, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ...   The live presentation takes place on ... 6:00 a.m. Pacific Time.  The presentation will be webcast and ...
Cached Medicine Technology:Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 2Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 3Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 4Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 5
(Date:9/16/2014)... DC September 14, 2014 A ... everolimus-eluting stents (EES) and drug-eluting balloons (DEB) ... stents found that EES provided superior late ... , Findings were reported today at ... scientific symposium. Sponsored by the Cardiovascular Research ...
(Date:9/16/2014)... that corn absorbs the right balance of nitrogen, phosphorus ... Purdue and Kansas State University study finds. , A ... the U.S. and other regions showed that high yields ... took up key nutrients at specific ratios - nitrogen ... and potassium at a ratio of 1-to-1. These nutrient ...
(Date:9/16/2014)... September 16, 2014 This year’s theme ... and Sustainable company Glen Mills, Pennsylvania, September 15, 2014- ... one of the fastest growing companies in the country, ... flower, shrub, and tree health-care by naturally decreasing disease ... development. Today it announced that it will hold its ...
(Date:9/16/2014)... Los Angeles, CA (PRWEB) September 16, 2014 ... the League of United Latin American Citizens (LULAC) will ... California. LULAC’s Feria de Salud will feature free health ... Other free testing includes glucose and cholesterol levels ... screenings will be available for children under 6 years ...
(Date:9/16/2014)... Almost all the various treatment options for blood ... and effective, new research shows. In exploring ... blood clots as deep vein thrombosis or pulmonary ... analyzed outcomes associated with eight blood-thinning options, including ... combination with vitamin K antagonists. The ...
Breaking Medicine News(10 mins):Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2Health News: Most Treatments for Blood Clots Appear Safe, Effective 2
... THURSDAY, June 9 (HealthDay News) -- Children are among those ... ocular toxocariasis (OT), which can lead to permanent vision loss, ... can occur when a person ingests dirt that,s contaminated with ... dog or cat. Larvae that emerge from the eggs migrate ...
... Should physicians be banned from assisting in a ... so? A recent ruling by the American Board of ... capital punishment, and other medical boards may act similarly. ... concludes that decertification of physicians participating in ...
... where to eat could literally tip the scales on his ... perceptions of family meals carry more weight, so to speak, ... recently in The Journal of Nutrition Education and Behavior ... special family time certainly do not see a fast-food restaurant ...
... stomach and pancreas could be detected much sooner with a ... of Edinburgh have identified key proteins in the urine of ... detection of these cancers in people who have not yet ... enable patients to be diagnosed much earlier, leading to improved ...
... HealthDay Reporter , WEDNESDAY, June 8 (HealthDay News) ... for a label warning on the popular statin Zocor because ... in the highest doses. This risk has been seen ... day, particularly during the first year of treatment, the agency ...
... into a wallet or pursebut it could mean the difference between ... stores personal medical data (e.g. information on existing medical conditions, allergies ... enabling the data to be accessed in just a few moments. ... have been trialled in the UK. This working prototype has ...
Cached Medicine News:Health News:Tainted Soil May Put Kids at Risk for Vision Loss 2Health News:Physician participation in lethal injection executions should not be banned, argue 2 ethicists 2Health News:Physician participation in lethal injection executions should not be banned, argue 2 ethicists 3Health News:Children eschew the fat if dads aren't lenient 2Health News:Children eschew the fat if dads aren't lenient 3Health News:Simple test could hold key to early diagnosis of cancers 2Health News:FDA Places New Warning Label on Zocor 2Health News:FDA Places New Warning Label on Zocor 3Health News:MyCare -- the 'card' that could save your life 2
Scoville cervical disc retractor, self-retaining with ratchet action....
... Image-Line offers superior retractor blade stability ... all cervical spine retraction objectives. The ... rapid and accurate blade size determination. ... accommodates a variety of patients and ...
Small, removable blades, length 178 mm, (7"). Function: tissue retracting....
The High Sensitivity C-Reactive Protein (RCRP) Flex reagent cartridge is an in vitro diagnostic test intended for the quantitative determination of CRP in serum and plasma. This assay is not availabl...
Medicine Products: